← All diseases Blood and bone marrow

Myelofibrosis

Automatically tracked from PubMed and ClinicalTrials.gov, newest on top. Nothing ever disappears here: what you keep in your favorites remains findable. · RSS feed of this disease · only the strongest evidence

Search Period All yearsLast 12 monthsLast 5 years Topic All topicsGeneralNutrition and dietAlternative treatment methods Type of research Any type of researchOnly the most rigorous evidence (43)Treatment guideline (6)Meta-analysis (5)Phase 3 study (19)Randomized trial (9)Systematic review (4)Clinical Trial (599)Review article (228)Early study (phase 1 or 2) (41)Case reports (176)Laboratory or animal research (16)Commentary or editorial (73)Retracted publication (1) Studies currently recruiting participants only (37)

Filter

Publications and studies (1631)

• The hematopoietic stem cells supportive megakaryocytes as shapers of the bone marrow niche. (2025/09/22) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Acute Myeloid Leukemia With RUNX1::RUNX1T1 Fusion Transformed From JAK2V617F-Mutated Polycythemia Vera: A Case Report. (2025/09/18) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Advancements in myelofibrosis management: a comprehensive analysis of Ojjaara (Momelotinib) therapy and clinical perspectives. (2025/09/12) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Final safety and efficacy results from a phase 1/2 study of tagraxofusp, a CD123-targeted therapy, for myelofibrosis. (2025/08/25) ♡
• Second malignancies among older patients with classical myeloproliferative neoplasms treated with ruxolitinib. (2025/08/19) ♡
• Prognostic Implications of Red Blood Cell Distribution Width to Albumin Ratio in Myelofibrosis: A 10-Year Multicenter and Retrospective Study. (2025/07/15) ♡
• Renal Impairment in Myeloproliferative Neoplasms: An Under-reported Complication. (2025/07/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. SOHO State of the Art Updates and Next Questions | Updates on Myelofibrosis With Cytopenia. (2025/05/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. A Review of Real-World Experience With Ruxolitinib for Myelofibrosis. (2025/05/01) ♡
• Different inflammatory, fibrotic, and immunological signatures between pre-fibrotic and overt primary myelofibrosis. (2025/04/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. New approaches to standard of care in early-phase myeloproliferative neoplasms: can interferon-α alter the natural history of the disease? (2025/04/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. What are the therapeutic options for previously treated myelofibrosis? (2025/04/01) ♡
• Incidental changes in hemoglobin levels in patients with myelofibrosis receiving treatment with sodium-glucose co-transporter-2 inhibitors. (2025/04/01) ♡
• Megakaryocyte centrosomal and Golgi structural perturbations in patients with primary myelofibrosis and with RUNX1 germline mutation. (2025/04/01) ♡
• Commentary or editorialiAn expert's opinion or commentary, not new research. A case of leukemia cutis in a patient with primary myelofibrosis diagnosed based on a folliculitis-like rash preceding the detection of leukemic cells in peripheral blood. (2025/04/01) ♡
• Extramedullary Hematopoiesis in Serous Cavity Fluids: A Closer Look at This Rare Phenomenon With Diagnostic Pitfalls and Prognostic Significance. (2025/04/01) ♡
• Adjunctive effects of eltrombopag on immunosuppressive therapy for childhood aplastic anemia. (2025/04/01) ♡
• Development of Autoimmune Hemolytic Anemia During Ruxolitinib Treatment for Myelofibrosis: A Case Series. (2025/04/01) ♡
• Early-stage study (phase 1 or 2)iEarly research in a small group, primarily aimed at safety and dosage. Whether it actually works still needs to be determined afterward. Longitudinal Assessment of Transfusion Intensity in Patients With JAK Inhibitor-Naive or -Experienced Myelofibrosis Treated With Momelotinib. (2025/03/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. When and how to transplant in myelofibrosis - recent trends. (2025/03/01) ♡
• Phase 3 studyiResearch in a large group of patients, the final step before a treatment can be approved. What comes out here carries significant weight. Myelofibrosis symptom assessment form total symptom score version 4.0: measurement properties from the MOMENTUM phase 3 study. (2025/03/01) ♡
• Earlier versus delayed ruxolitinib treatment for patients with myelofibrosis: a plain language summary. (2025/03/01) ♡
• HMGA2 overexpression with specific chromosomal abnormalities predominate in CALR and ASXL1 mutated myelofibrosis. (2025/03/01) ♡
• Pretransplant Chromosome Genomic Array Testing Improves Prognostication for Myelofibrosis Patients Undergoing Transplantation. (2025/03/01) ♡
• Commentary or editorialiAn expert's opinion or commentary, not new research. Outcome of Splenectomy in JAK2 Inhibitor Treated Patients With Myelofibrosis: A Mayo Clinic Experience in 34 Consecutive Cases. (2025/03/01) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Pacritinib Response Is Associated With Overall Survival in Myelofibrosis: PERSIST-2 Landmark Analysis of Survival. (2025/02/01) ♡
• Inter-racial genetic differences in myelofibrosis: a diverse inner-city center analysis. (2025/02/01) ♡
• Features and Allele Frequency of JAK2 Exon 12-Mutated Polycythemia Vera in Comparison with JAK2V617F-Mutated Disease. (2025/02/01) ♡
• Commentary or editorialiAn expert's opinion or commentary, not new research. Fedratinib as an alternative to splenectomy for refractory splenomegaly prior to transplant for myelofibrosis. (2025/02/01) ♡
• Clinical and Immune Effects of Peri-Transplantation JAK Inhibition for Myelofibrosis. (2025/02/01) ♡
• Commentary or editorialiAn expert's opinion or commentary, not new research. Basophilia Predicts Poorer Outcomes in Essential Thrombocythemia, Polycythemia Vera, Primary Myelofibrosis, and Myeloproliferative Neoplasm, Unclassifiable. (2025/02/01) ♡
• Commentary or editorialiAn expert's opinion or commentary, not new research. Hematopoietic Stem Cell Transplantation in Patients With Myelofibrosis and Splanchnic Vein Thrombosis: A Case Series. (2025/02/01) ♡
• Development and validation of a deep learning model for morphological assessment of myeloproliferative neoplasms using clinical data and digital pathology. (2025/02/01) ♡
• Commentary or editorialiAn expert's opinion or commentary, not new research. Peri-Transplant Management of JAK Inhibitor Therapy in Myelofibrosis. (2025/02/01) ♡
• Exploring Drug Repurposing for Interstitial Cystitis/Bladder Pain Syndrome: Defining Novel Therapeutic Targets. (2025/02/01) ♡
• Commentary or editorialiAn expert's opinion or commentary, not new research. Nodal mature plasmacytoid dendritic cell proliferation mimicking lymphoma in a patient with CALR-mutated myelofibrosis. (2025/02/01) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Real-world experience with pacritinib for patients with myelofibrosis refractory to ruxolitinib: a report of three cases. (2025/02/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Navigating 'grey areas' and challenges during evaluation of transplant eligibility in specific myelofibrosis populations: a perspective on behalf of the Chronic Malignancies Working Party of the EBMT. (2025/01/01) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Oral administration of ruxolitinib in psoriasis vulgaris: A case report of plaque psoriasis accompanied by myelofibrosis secondary to polycythemia vera successfully treated with oral ruxolitinib. (2025/01/01) ♡
• Real-World Use of Ruxolitinib in Patients with Myelofibrosis and Anemia or Thrombocytopenia at Diagnosis. (2025/01/01) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Evaluation and management of hepatic dysfunction, portal hypertension and portal/splanchnic vein thrombosis in patients with myelofibrosis undergoing allogeneic haematopoietic cell transplantation: A practice based survey on behalf of the Chronic Malignancies Working Party of the EBMT. (2025/01/01) ♡
• Analysis of Molecular Testing for Suspected Myeloproliferative Neoplasm at a Hybrid Community-Academic Health System. (2025/01/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Ten years of experience with ruxolitinib since approval for polycythemia vera: A review of clinical efficacy and safety. (2025/01/01) ♡
• Randomized researchiParticipants were divided into groups by lottery and compared with each other. This reduces the chance that a difference is due to something other than the treatment. Pharmacokinetics of Zilurgisertib With and Without Food from Single and Multiple Ascending Dose Phase 1 Studies in Healthy Adults. (2025/01/01) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Whole exome sequencing analysis of a patient with myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions with ETV6::LYN fusion gene. (2025/01/01) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Dasatinib as Therapy for Myeloproliferative Disorders (MPDs) (2025-12-30) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Selumetinib and Azacitidine in High Risk Chronic Blood Cancers (2025-12-29) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. MethoTRExATE in MyelOpRolifErative Neoplasms (TREATMORE) Trial (2025-12-17) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. A Study to Evaluate Drug-Drug Interaction of TQ05105 Tablets (2025-12-12) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. CMV-MVA Triplex Vaccination of Stem Cell Donors in Preventing CMV Viremia in Participants With Allogeneic Transplant (2025-12-10) ♡

↑ Back to top

codex.care does not provide medical advice. Always discuss symptoms, medication, and treatment choices with your own healthcare provider.